AVRO Projected Dividend Yield
AVROBIO Inc ( NASDAQ : AVRO )AVROBIO is a clinical-stage gene therapy company focused on developing potentially curative ex vivo lentiviral gene therapies to treat patients with rare diseases following a single dose treatment regimen. Co.'s gene therapies employ hematopoietic stem cells (HSC) that are harvested from the patient and then modified with a lentiviral vector to insert the functional copy of the gene that is mutated in the target disease. Co. has four HSC gene therapy programs: VR-RD-02 for the treatment of Gaucher disease type 1 and type 3; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of neuronopathic mucopolysaccharidosis type II; and AVR-RD-03 for the treatment of Pompe disease. 20 YEAR PERFORMANCE RESULTS |
AVRO Dividend History Detail AVRO Dividend News AVRO Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |